Skip to main content

Table 1 Characteristics of subjects by Fiebig and 4th generation enzyme immunoassay staging system at the time of acute HIV infection diagnosis and week 24 after initiating antiretroviral therapy

From: A novel acute HIV infection staging system based on 4thgeneration immunoassay

 

Fiebig stages

4thG stages

 

Stage I

Stage II

Stage III

Stage IV

Stage 1

Stage 2

Stage 3

 

NAT+/p24-/3rdG-(n=25)

NAT+/P24+/3rdG-(n=7)

NAT+/p24±/3rdG+/WB-(n=29)

NAT+/p24±/3rdG+/WB IND (n=2)

NAT+/4thG-/3rdG-(n=20)

NAT+/4thG+/3rdG-(n=12)

NAT+/4thG+/3rdG+/WB- or IND (n=31)

At time of acute HIV infection diagnosis (n=63)

Median (IQR) days from history of HIV exposure

14 (9–18)

15 (11–17)

18* (13–22)

26 (NA)

12 (9–15)

17* (15–21)

18* (13–22)

Range (Min-Max)

(4–40)

(9–18)

(9–33)

(20–32)

(4–40)

(10–34)

(9–33)

Median (IQR) HIV RNA, log10copies/mL

5.1 (4.1-5.4)

5.8 * (5.1-6.5)

5.9 ** (5.6-6.9)

5.6 (NA)

4.8 (3.7-5.4)

5.8** (5.4-6.2)

5.8** (5.6-6.9)

Range (Min-Max)

(2.8-6.1)

(5.1-7.6)

(4.7-7.7)

(5.5-5.8)

(2.8-5.7)

(5.1-7.6)

(4.7-7.7)

Median(IQR) p24 pg/mL

3.9 (0–20.1)

190** (124–794)

262** (46.1-937.2)

106 (NA)

0.3 (0–27.4)

54.3* (14.7-203.5)

227.3** (42.6-937.2)

Range (Min-Max)

(0–65)

(74.3-862)

(15.7-6973.9)

(16.9-195)

(0–133.9)

(3.7-862)

(15.7-6973.9)

Median(IQR) CD4 cells/mm3

413 (311–565)

289 (218–426)

381 (298–428)

371 (NA)

451 (316–592)

316 (265–420)

381 (295–463)

Range (Min-Max)

(214–1127)

(179–569)

(132–621)

(279–463)

(218–1127)

(179–698)

(132–621)

At week 24 after antiretroviral therapy (n=61, excluded 2 subjects who did not start treatment)*

Median (IQR) days from diagnosis to ART initiation

2 (2–3)

2 (1–2)

2 (1–3)

2 (NA)

2 (2–4)

2 (1–2)

2 (1–3)

Range (Min-Max)

(0–5)

(0–2)

(0–5)

(1–3)

(1–5)

(0–4)

(0–5)

Median (IQR) HIV RNA

1.7

1.7

1.7

1.7

1.7

1.7

1.7

log10copies/mL

(1.7-1.7)

(1.7-1.7)

(1.7-1.7)

(NA)

(1.7-1.7)

(1.7-1.7)

(1.7-1.7)

Range (Min-Max)

(1.7-1.7)

(1.7-2.0)

(1.7-2.2)

(1.7-1.7)

(1.7-1.7)

(1.7-2.0)

(1.7-2.2)

Median change (IQR) HIV RNA log10copies/mL

-3.4 (-3.7 to -2.4)

-3.8* (-4.7 to -37)

-4.2 ** (-5.2 to -3.9)

-3.9 (-4.1 to -3.8)

-3.0 (-3.7 to -1.9)

-4.0* (-4.4 to -3.7)

-4.1** (-5.2 to -3.8)

Range (Min-Max)

(-4.4 to -1.1)

(-4.8 to -3.4)

(-6.0 to -3.0)

(-4.1 to -3.8)

(-4.0 to -1.1)

(-4.8 to -3.4)

(-6.0 to -3.0)

Median (IQR) CD4 cells/mm3

600 (540–904)

766 (523–772)

579 (486–730)

821 (NA)

597 (483–794)

904* (556–1056)

579 (470–765)

Range (Min-Max)

(312–1084)

(354–1145)

(301–1229)

(462–1180)

(312–979)

(503–1145)

(301–1229)

Median change (IQR) CD4 cells/mm3

256 (50–358)

344 (203–477)

227 (180–320)

450 (NA)

136 (-25 to 280)

477** (291–719)

227* (180–347)

Range (Min-Max)

(-237-766)

(136–719)

(-135-804)

(183–717)

(-237-383)

(203–766)

(-135-804)

Nonreactive 2nd generation EIA, N

10

0

4

1

9

1

5

Nonreactive/IND WB, N

11

0

4

1

11

0

5

  1. P value compared to stage 1 within each staging system: *p < 0.05, **p < 0.001 All patients had non-reactive 2nd generation enzyme immunoassay, negative/indeterminate Western Blot and positive nucleic acid testing.
  2. Abbreviations used: NAT nucleic acid testing; 3rdG 3rd generation enzyme immunoassay; 4thG 4th generation enzyme immunoassay; EIA enzyme immunoassay; WB Western blot; IND indeterminate; IQR inter-quartile range; NA not applicable.
  3. *Two patients did not start ART; they were both in Fiebig II stage while one was in 4thG stage1 and the other in 4thG stage2.
Back to article page

Retrovirology

ISSN: 1742-4690

Contact us